Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55

Veracyte, Inc.

Veracyte, Inc.

VCYT

0.00

Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ: VCYT) with a Overweight and lowers the price target from $68 to $55.